摘要
目的分析吡格列酮二甲双胍联合二肽基肽酶(dipeptidyl peptidase-4,DPP4)抑制剂治疗2型糖尿病的有效性与不良反应。方法选取2022年1月-2023年12月盐城市第一人民医院收治的160例2型糖尿病患者为研究对象,根据不同的治疗方式分为两组,单一组(80例,使用吡格列酮二甲双胍治疗)和联合组(80例,吡格列酮二甲双胍联合DPP4抑制剂治疗),以血糖水平、血脂水平、胰岛β细胞功能、不良反应发生率作为观察指标进行组间比较。结果治疗前,两组血糖、血脂、胰岛β细胞功能等指标水平相似,差异均无统计学意义(P均>0.05);治疗后,较单一组,联合组糖化血红蛋白胆固醇水平、空腹血糖水平、餐后2 h血糖水平更低,差异均有统计学意义(P均<0.05)。联合组低密度脂蛋白水平、甘油三酯水平、总胆固醇水平更低,稳态模型胰岛抵抗指数更低,稳态模型胰岛β细胞功能指数更高,差异均有统计学意义(P均<0.05)。组间比较恶心呕吐、食欲下降、头痛、低血糖等不良反应总发生率,差异无统计学意义(P>0.05)。结论吡格列酮二甲双胍、DPP4抑制剂联合用药方案可有效控制2型糖尿病患者的血糖血脂水平,改善胰岛功能,不会增加不良反应,具有较好的安全性。
Objective To analyze the efficacy and adverse reactions of pioglitazone metformin combined with dipepti-dyl peptidase-4(DPP4)inhibitor in the treatment of type 2 diabetes.Methods A total of 160 patients with type 2 dia-betes admitted to Yancheng First People's Hospital from January 2022 to December 2023 were selected as the re-search objects.According to different treatment methods,they were divided into two groups,single group(80 cases,treated with pioglitazone metformin)and combined group(80 cases,treated with pioglitazone metformin combined with DPP4 inhibitor).Blood glucose level,blood lipid level,isletβcell function and incidence of adverse reactions were compared between the two groups.Results Before treatment,the levels of blood glucose,blood lipid and isletβcell function were similar between the two groups,and the differences were not statistically significant(all P>0.05).After treatment,the levels of glycosylated hemoglobin,fasting blood glucose and 2-hour postprandial blood glucose in the combined group were lower than those in the single group,and the differences were statistically significant(all P<0.05).The levels of low density lipoprotein cholesterol,triglyceride and total cholesterol in the combined group were lower,the islet resistance index in the steady-state model was lower,and the isletβ-cell function index in the steady-state model was higher,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions such as nausea and vomiting,loss of appetite,headache and hypoglycemia between the two groups(P>0.05).Conclusion The combination of pioglitazone metformin and DPP4 inhibitor can effectively control the blood glucose and lipid levels of patients with type 2 diabetes,improve islet function,and will not increase adverse reactions,with good safety.
作者
何舒婷
黄珊珊
邵思维
HE Shuting;HUANG Shanshan;SHAO Siwei(Department of Pharmacy,Yancheng First People's Hospital,Yancheng 224000,Jiangsu,China)
出处
《糖尿病新世界》
2025年第8期99-102,共4页
Diabetes New World
关键词
糖尿病
吡格列酮二甲双胍
二肽基肽酶
胰岛功能
不良反应
Diabetes mellitus
Pioglitazone metformin
Dipeptidyl peptidase-4
Islet function function
Adverse reac-tions
作者简介
何舒婷(1986-),女,本科,主管药师,研究方向为临床药学。
